IL6 and infection: This is interesting since tocilizumab has often been associated with an increased risk of infection, yet in our findings from real-world data, tocilizumab/sarilumab showed a lower rate of post-treatment infections requiring hospital treatment compared with non-anti-IL-6 bDMARDs.